复方苦参注射液联合FOLFOX4治疗78例晚期结直肠癌患者的临床疗效以及生存分析

目的 探究复方苦参注射液联合FOLFOX4治疗晚期结直肠癌的疗效及安全性。方法 选取我院2015年5月—2018年4月确诊为晚期结直肠癌且采取化疗措施的78例患者，随机分为两组，对照组患者采取FOLFOX4方案化疗，观察组患者采取复方苦参注射液联合FOLFOX4方案治疗，所有患者均完成4个周期的治疗。比较两组患者的治疗效果、化疗期间不良反应发生情况、免疫指标变化情况和1年生存情况。结果 治疗后，两组患者化疗有效率比较，差异无统计学意义（P=0.062），观察组患者疾病进展率显著低于对照组（P=0.028）；观察组患者骨髓抑制、胃肠道反应和神经毒性反应的发生率均显著低于对照组（P=0.030、0.001、0.003）；对照组患者免疫功能较治疗前显著下降，而观察组患者免疫功能无明显下降；观察组患者1年无进展生存率显著高于对照组（23.08% vs. 7.69%， P=0.017），两组患者的总生存期比较，差异无统计学意义（P=0.290）。结论 复方苦参注射液联合FOLFOX4治疗晚期结直肠癌具有较好的疗效，不良反应发生率低，而且有助于保护患者的免疫功能。

Clinical efficacy and survival analysis of compound Kushen injection combined with FOLFOX4 in the treatment of 78 patients with advanced colorectal cancer

Objective To explore the efficacy and safety of compound Kushen injection (CKI) combined with FOLFOX4 in the treatment of advanced colorectal cancer (CRC).Methods A total of 78 patients who were diagnosed with advanced CRC in our hospital between May 2015 and April 2018 and received chemotherapy were selected in this study. They were randomly divided into two groups. The control group received FOLFOX4 treatment, and the observation group received CKI combined with FOLFOX4 treatment. All patients underwent 4 cycles of treatment. Compare the treatment effects, the incidence of adverse reactions during chemotherapy, the changes in immune indicators and the 1-year survival rate between the two groups.Results After treatment, there was no significant difference in the effective rate between the two groups (P=0.062), but the disease progression rate was lower in the observation group than in the control group (P=0.028). The incidence rates of bone marrow suppression, gastrointestinal reactions and neurotoxic reactions were significantly lower in the observation group than in the control group (P=0.030, P=0.001, P=0.003). The immune function of patients in the control group declined significantly after treatment, while that in the observation group showed no changes. The 1-year progression-free survival rate of the observation group was higher than that of the control group (23.08% vs. 7.69%, P=0.017). In terms of overall survival, there was no significant difference between the two groups (P=0.290).Conclusion The CKI combined with FOLFOX4 has a good effect in the treatment of advanced CRC. It can reduce the incidence of adverse reactions, and help to protect the immune function of patients.